Tags

Type your tag names separated by a space and hit enter

Treating the symptoms of gastro-oesophageal reflux disease: a double-blind comparison of omeprazole and cisapride.
Aliment Pharmacol Ther 1997; 11(4):765-73AP

Abstract

BACKGROUND

Few studies have specifically addressed the management of the symptoms of gastro-oesophageal reflux disease, and there are no comparative data in this respect for acid pump inhibitors and prokinetic agents.

METHODS

Following endoscopy 424 patients presenting with heartburn as the predominant symptom of gastro-oesophageal reflux disease were randomized to treatment with omeprazole 20 or 10 mg once daily, or cisapride 10 mg four times daily, in a double-blind, double-dummy, parallel group, multicentre study. Symptoms and quality of life were assessed at 4 weeks. Patients still experiencing heartburn continued therapy for a further 4 weeks and the assessments were repeated.

RESULTS

At 4 weeks, heartburn was resolved in 65% (95% CI: 57-73%), 56% (48-64%) and 41% (32%-49%) of patients treated, respectively, with omeprazole 20 mg and 10 mg once daily, and cisapride. Both omeprazole doses were significantly more effective than cisapride (P < 0.01). The same order of efficacy was observed regardless of the presence of erosive oesophagitis. Regurgitation and epigastric pain also improved to a greater degree with omeprazole than with cisapride. Quality of life was improved in all treatment groups, and the improvement in the reflux dimension of the Gastrointestinal Symptom Rating Scale (GSRS) score was significantly different between groups (P = 0.002).

CONCLUSIONS

Omeprazole 20 or 10 mg once daily is significantly more effective than cisapride in the resolution of heartburn, regardless of the presence of erosive oesophagitis, and this is accompanied by an improvement in patient quality of life.

Authors+Show Affiliations

Department of Gastroenterology, Hotel Dieu, Nantes, France.No affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

9305487

Citation

Galmiche, J P., et al. "Treating the Symptoms of Gastro-oesophageal Reflux Disease: a Double-blind Comparison of Omeprazole and Cisapride." Alimentary Pharmacology & Therapeutics, vol. 11, no. 4, 1997, pp. 765-73.
Galmiche JP, Barthelemy P, Hamelin B. Treating the symptoms of gastro-oesophageal reflux disease: a double-blind comparison of omeprazole and cisapride. Aliment Pharmacol Ther. 1997;11(4):765-73.
Galmiche, J. P., Barthelemy, P., & Hamelin, B. (1997). Treating the symptoms of gastro-oesophageal reflux disease: a double-blind comparison of omeprazole and cisapride. Alimentary Pharmacology & Therapeutics, 11(4), pp. 765-73.
Galmiche JP, Barthelemy P, Hamelin B. Treating the Symptoms of Gastro-oesophageal Reflux Disease: a Double-blind Comparison of Omeprazole and Cisapride. Aliment Pharmacol Ther. 1997;11(4):765-73. PubMed PMID: 9305487.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Treating the symptoms of gastro-oesophageal reflux disease: a double-blind comparison of omeprazole and cisapride. AU - Galmiche,J P, AU - Barthelemy,P, AU - Hamelin,B, PY - 1997/8/1/pubmed PY - 1997/9/26/medline PY - 1997/8/1/entrez SP - 765 EP - 73 JF - Alimentary pharmacology & therapeutics JO - Aliment. Pharmacol. Ther. VL - 11 IS - 4 N2 - BACKGROUND: Few studies have specifically addressed the management of the symptoms of gastro-oesophageal reflux disease, and there are no comparative data in this respect for acid pump inhibitors and prokinetic agents. METHODS: Following endoscopy 424 patients presenting with heartburn as the predominant symptom of gastro-oesophageal reflux disease were randomized to treatment with omeprazole 20 or 10 mg once daily, or cisapride 10 mg four times daily, in a double-blind, double-dummy, parallel group, multicentre study. Symptoms and quality of life were assessed at 4 weeks. Patients still experiencing heartburn continued therapy for a further 4 weeks and the assessments were repeated. RESULTS: At 4 weeks, heartburn was resolved in 65% (95% CI: 57-73%), 56% (48-64%) and 41% (32%-49%) of patients treated, respectively, with omeprazole 20 mg and 10 mg once daily, and cisapride. Both omeprazole doses were significantly more effective than cisapride (P < 0.01). The same order of efficacy was observed regardless of the presence of erosive oesophagitis. Regurgitation and epigastric pain also improved to a greater degree with omeprazole than with cisapride. Quality of life was improved in all treatment groups, and the improvement in the reflux dimension of the Gastrointestinal Symptom Rating Scale (GSRS) score was significantly different between groups (P = 0.002). CONCLUSIONS: Omeprazole 20 or 10 mg once daily is significantly more effective than cisapride in the resolution of heartburn, regardless of the presence of erosive oesophagitis, and this is accompanied by an improvement in patient quality of life. SN - 0269-2813 UR - https://www.unboundmedicine.com/medline/citation/9305487/Treating_the_symptoms_of_gastro_oesophageal_reflux_disease:_a_double_blind_comparison_of_omeprazole_and_cisapride_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&amp;sid=nlm:pubmed&amp;issn=0269-2813&amp;date=1997&amp;volume=11&amp;issue=4&amp;spage=765 DB - PRIME DP - Unbound Medicine ER -